enGene Inc. Common Stock (ENGN)
undefined
undefined%
At close: undefined
6.00
-1.15%
After-hours Dec 13, 2024, 04:14 PM EST

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Inc. Common Stock
enGene  Inc. Common Stock logo
Country CA
IPO Date Feb 1, 2022
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Ronald H. W. Cooper

Contact Details

Address:
7171 Rue Frederick Banting
Saint-Laurent,
CA
Website https://www.engene.com

Stock Details

Ticker Symbol ENGN
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0001100663
CUSIP Number n/a
ISIN Number CA29286M1059
Employer ID 94-3351276
SIC Code

Key Executives

Name Position
Ronald H. W. Cooper Chief Executive Officer & Director
David Ryan Daws Chief Financial Officer & Head of Business Development
Joan Connolly Chief Technology Officer
Lee G. Giguere Chief Legal Officer & Corporate Secretary
Dr. Anthony T. Cheung Ph.D. Co-Founder & Chief Scientific Officer
John C. Brown D.Sc., FRSC, Ph.D. Co-Founder and Member of Scientific Advisory Board
Paul Erickson Non-Executive Director
Sharon Tan Vice President of Project Management & Head of Program Management

Latest SEC Filings

Date Type Title
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 13, 2024 485APOS Filing
Dec 11, 2024 497K Filing
Dec 11, 2024 CERT Filing
Dec 06, 2024 POS EX Filing